Piramal Pharma Limited (PPLPHARMA) reported revenue of ₹2,270 Cr and a net loss of ₹69.39 Cr for the quarter ended 2026-06-30. Figures are parsed from the company's filed results.
PPLPHARMA fundamentals, Fundamental score 37/100
The statements below are read from Piramal Pharma Limited’s filed results, 14 filed quarters and 6 fiscal years on record, consolidated basis. Price-linked ratios are computed at the last close, sector medians across the served universe, ownership from the shareholding pattern, and any cell whose input isn’t on record shows a dash, never an estimate.
Latest: Q1 FY26-27 · filed Jul 30, 2026 · audited
Sales CAGR · 3Y+7.8%FY22 → FY25
Sales CAGR · 4Y+7.8%FY21 → FY25
PAT CAGR · 3Y—FY22 → FY25
PAT CAGR · 4Y—FY21 → FY25
Price · 1Y+7.7%EOD
Price CAGR · 3Y+27.6%EOD
Quarterly resultsConsolidated
₹ Cr
Dec2022
Jun2023
Sep2023
Dec2023
Mar2024
Jun2024
Sep2024
Dec2024
Mar2025
Jun2025
Sep2025
Dec2025
Mar2026
Jun2026Latest
YoYlatest
Sales
1,716
1,749
1,911
1,959
2,552
1,951
2,242
2,204
2,754
1,934
2,044
2,140
2,752
2,270
+17.4%
1,629
1,617
1,646
1,690
2,022
1,747
1,900
1,866
2,193
1,827
1,885
1,944
2,291
2,075
+13.6%
Operating profit
87.3
132
266
268
530
204
342
338
561
107
159
196
461
195
+82.9%
OPM %
5.1%
7.6%
13.9%
13.7%
20.8%
10.5%
15.2%
15.3%
20.4%
5.5%
7.8%
9.1%
16.7%
8.6%
+3.1 pp
Other income
82.5
38.3
49.2
61.5
26.4
19.5
61.1
12.1
42.0
58.4
65.6
43.2
46.1
89.4
+53.1%
Interest
94.7
119
110
106
114
107
108
103
104
86.2
82.4
89.2
83.0
88.1
+2.2%
Depreciation
164
174
185
186
196
185
192
197
243
197
203
213
218
224
+13.3%
Profit before tax
-89.2
-121
20.5
5.41
215
-67.5
103
49.8
257
-97.6
-61.0
-104
29.4
-27.0
n/m
Tax %
n/a (loss)
n/a (loss)
168.9%
171.0%
58.6%
n/a (loss)
94.8%
126.9%
46.5%
n/a (loss)
n/a (loss)
n/a (loss)
176.1%
n/a (loss)
—
Net profit
-90.2
-98.6
5.02
10.1
101
-88.6
22.6
3.68
154
-81.7
-99.2
-136
-8.82
-69.4
n/m
EPS (₹)
-0.76
-0.83
0.04
0.08
0.77
-0.67
0.17
0.03
1.16
-0.62
-0.75
-1.03
-0.07
-0.52
n/m
One column per filed quarter · ₹ crore · YoY = latest vs the same quarter a year back · EPS restated for bonus/split · n/a (loss) = tax rate undefined on a loss↔ scroll for earlier quarters
Revenue & net profit trend
last 14 quarters
RevenueNet profit
Revenue & net profit — Consolidated14 quarters
Segment results
Needs segment dataSegment results not parsedPer-segment revenue, EBIT margin and YoY arrive once we parse the segment annexure from the filing.
Forensic checksauto-scanned from the filing
Coming soonForensic checks not connectedAuditor opinion, OCF÷PAT, contingent liabilities, related-party share and working-capital days arrive as we parse the notes-to-accounts + cash-flow statement. Promoter-pledge is already on the Holdings tab.
How results moved the priceEOD reaction on the session the market could trade the filing
Avg absolute result-day move ±4.1%· EPS surprise: no estimates source
